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 Figure S1: Dynamic survival probabilities with 95% CI based on serial measurements of 
NT-proBNP for a patient whose values rose. The vertical dotted lines show the time point of 
the last log(NT-proBNP) measurement; prior values are shown to the left of the vertical line. 
The curves to the right are the survival probabilities incorporating all the NT-proBNP data to 
that point (x-axis: Time (years), y-axis: Longitudinal Outcome shows the observed values of 
log10(NT-proBNP) at each follow-up time point. 
 
 Figure S2: Dynamic survival probabilities with 95% CI based on serial measurements of 
NT-proBNP for a patient with lower and fairly stable measurements. The vertical dotted lines 
show the time point of the last log(NT-proBNP) measurement; prior values are shown to the 
left of the vertical line. The curves to the right are the survival probabilities incorporating all 
the NT-proBNP data to that point (x-axis: Time (years), y-axis: Longitudinal Outcome shows 
the observed values of log10(NT-proBNP) at each follow-up time point. 
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Supplemental table S1 
Table: S1_A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute HF Type of study HF phenotype Number of 
patients 
NP measurements Potential modifiers of 
BNP 
Findings 
Bettencourt et al 
2004 (1) 
Observational  
 
ADHF 182 Measured every day 
until discharge 
Length of stay 
Heart rate 
Volume overload signs 
No ACEi 
Higher discharge NYHA 
Patients who were readmitted had higher  NT-proBNP  
 
 
Changes in NT-proBNP were associated with mortality and 
readmission  
Logeart et al 2003 
(2) 
Observational;  
 
 
 
 
ADHF  114 Measured every day 
until discharge 
High LV filling pressures  High pre-discharge BNP is a strong independent marker of death 
or readmission after decompensated HF. Those with value 
<300pg/mL had lowest readmission rates.  
 
Patients with the greatest decrease in BNP had the best outcome 
O’Brien et al 2003 
(3) 
Observational ADHF 96 At admission, 
discharge 
 Pre-discharge rather than admission BNP concentration is better 
predictor of death/readmission with HF.  
 
NO association between magnitude/direction of change in NT-
proBNP and occurrence of death/hospitalisation 
Gackowski et al 
2004 (4) 
Observational ADHF 95 At admission, after 24 
hours, and 7th day/at 
discharge.  
 Serial measurements of BNP plasma levels provide incremental 
prognostic information over clinical and echocardiographic data in 
high-risk populations  
Cheng et al, 2000 
(5) 
Observational ADHF  72 Within 24 hours of 
admission and prior to 
discharge 
NYHA classification Patients who died or were readmitted tended to have increase in 
BNP during hospitalisation, those who had successful treatment 
tended to have decreases in their BNP concentration during 
hospitalisation 
 
A final BNP level <430pg/ml had a strong negative predictive value 
for 30 day readmission.   
Greene et al, 
2015(6)  
ASTRONAUT ADHF  
EF <40%, 
BNP >400pg/mL 
NT-roBNP >1600pg/ml  
1,351  Measured at 
admission,  5 days and 
1m 
 
 
Weight loss / 
decongestion, renal 
dysfunction, AF 
 
NT-proBNP 1 month post-discharge but not during admission 
predicted cardiovascular readmission/decompensation but not all 
cause mortality.  
Maisel et al, 2013 
(7) 
Observational 
study, monitoring 
daily 
concentrations of 
BNP  
ADHF 163 Peri-discharge then 
daily until day 60.  
 Correlations between BNP measurements weakened over time.  
 
Hazard ratio per unit increase of BNP was 1.84. Upward trending 
BNP corresponded to risk increase of 59.8% and downward 
trending BNP corresponded to risk decrease of 39.0%.  
Wu et al, 2006 (8) Observational 
study of multiple 
studies 
    For inpatient monitoring, serial BNP/NT-pro BNP measurements 
are useful for detecting short-term improvements with diuretics. 
BNP/NT-proBNP concentrations double in patients with stable HF 
who suddenly decompensate.  
 
  
 
Table: S1_B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic HF Type of study HF phenotype Number of 
patients 
NP measurements Potential modifiers of 
BNP 
Findings 
Masson et al 2008 (9) Placebo arm of Val-
HF 
LVEF <40% 1,742 Baseline & at 4 
months 
 Achieved NT-proBNP more important than change  
Anand et al 2007(10)  RCT Val-HF  
 
 
 
 
LVEF<40% 4,305 Baseline, to 4 months 
and 12 months 
Valsartan caused a 
sustained reduction in 
BNP regardless of trend 
BNP changes over time are associated with corresponding changes 
in subsequent mortality and morbidity 
 
% change are relevant for morbidity and mortality 
Zile et al, 2006(11) RCT PARADIGM-HF LVEF <35% 
BNP >100pg/ml 
NT-
proBNP>400pg/ml 
2,080 Baseline, 1 month and 
8 months 
Sacubitril/valsartan 
nearly twice as likely as 
enalapril to reduce NT-
proBNP to values < 
1,000pg/ml 
Percent reduction from baseline similarly important, regardless of 
treatment. 
 
Risk of primary endpoint was 59% lower in patients with a fall in 
NT-proBNP to <1,000pg/ml than in those without such a fall. 
Kubanek et al 2009(12)  Observational LVEF<45% 361 Baseline, 4th month 
and 6th month 
 Plasma NT-proBNP levels are the strongest predictor of mortality 
and first unplanned CV hospitalisation. 
NT-proBNP levels after optimization of pharmacotherapy better 
predict subsequent mortality and CV hospitalization events than 
baseline values or change between baseline and follow-up 
Gardner et al, 2007(13) Prospective 
observational 
LVEF <35% 112 Baseline and at 4 
months 
 NT-proBNP above the median and a change in NT-proBNP 
concentration over a 4 month period were independent predictors 
of mortality in patients with advanced heart failure 
O’Hanlon et al, 2006 
(14) 
Observational study, 
evaluating intra-
individual variability 
of BNP and NT-
proBNP 
Stable HF patients   45 1 hour apart on day 1, 
then at one week.  
 Large intra-individual variability in clinically stable HF patients, 
both within 1 hour and in samples taken 1 week apart.  
Care needs to be taken when interpreting changes in natriuretic 
peptide levels when monitoring a patient’s response to 
therapy/assessing clinical status. 
Wu et al, 2006 (8) Observational study, 
monitoring daily 
concentrations of 
BNP  
    In long term outpatient monitoring, changes in BNP-NT-proBNP do 
not exceed their normal biological variance. 
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Table S2: Correlations between log(NT-proBNP) measurements at baseline, 4, 12 and 24 months 
NT-proBNP Median with IQR for groups: all 
patients/AF/SR groups 
The number of 
patients in each 
group 
Correlations co-efficients for log(NT-proBNP) measured at 
various times (p<0.0001 for all) 
 
Baseline 
 
4 months 
 
12 months 
Baseline All:      1,108 (448-2613) 
AF:      1,878 (1026-3527) 
SR:         828 (311-2080) 
1998 
  614 
1384 
   
4 months All:          969 (393-2109) 
AF:       1,530 (880-2816) 
SR:          694 (297-1670) 
1314 
  426 
  888 
0.82 
0.70 
0.83 
  
12 months All:           863 (354-1981) 
AF:        2,952 (1649-2952) 
SR:           586 (272-1380) 
1168 
  355 
  813 
0.74 
0.57 
0.75 
0.84 
0.73 
0.83 
 
24 months All:            825 (318-1928) 
AF:         2,862 (1412-2862) 
SR:            606 (253-1510) 
  930 
  251 
  679 
0.68 
0.55 
0.68 
0.79 
0.70 
0.79 
0.83 
0.74 
0.86 
Abbreviations: AF: Atrial fibrillation; SR: Sinus rhythm. 
Supplemental table S3: Survival models for all-cause mortality for long-term prediction* 
 Log(NT-proBNP) 
HR (95%CI) z-statistic p-value 
Starting from baseline 
Cox regression for baseline data 1.81 (1.58 - 2.08) 8.56 <0.0001 
Joint modelling for all follow-up  3.76 (3.15 - 4.56) 13.24 <0.0001 
Joint modelling for all follow-up 
excluding last data 
3.01 (2.20 - 3.21) 11.07 <0.0001 
Starting from most recent data 
Cox regression for most recent data 3.73 (3.20-4.34) 16.89 <0.0001 
*The models were adjusted for pre-specified baseline age, sex and eGFR (Estimated glomerular 
filtration rate).  
